Selectively targeting specific cytokines (TNF-α, IL-17 and IL-12/23) and/or intracellular signaling pathways effectively prevent disease progression by ameliorating cutaneous inflammation of psoriasis and inhibiting osteoclastogenesis. Here, IL17A is linked to psoriasis.